News Medical on MSN12d
Cancer-free for 18 years: CAR-T therapy sets new milestone in neuroblastoma treatment
A groundbreaking study in Nature Medicine reveals that GD2 CAR-T cell therapy can lead to long-term remission in children ...
Medical Xpress13d
Patient with nerve cell cancer in remission for 18 years following CAR-T therapy
Helen Heslop and colleagues conducted a phase 1 clinical trial involving 19 children with neuroblastoma, between 2004 and ...
Nasdaq1mon
Y-mAbs Presents GD2-SADA Pharmacokinetics Data At SNMMI And ACNM Annual Meeting
(RTTNews) - Y-mAbs Therapeutics, Inc. (YMAB), a commercial-stage biopharmaceutical company presented preclinical and translational pharmacokinetics or PK data of GD2-SADA at the 2025 SNMMI Mid ...
Nasdaq1mon
Y-mAbs Therapeutics Presents Preclinical Data on GD2-SADA at SNMMI/ACNM Annual Meeting
Y-mAbs Therapeutics, Inc. has presented preclinical and translational pharmacokinetic data of their GD2-SADA bispecific fusion protein at the 2025 Society of Nuclear Medicine & Molecular Imaging ...